Search - tctmd.com

Displaying 521 - 540 of 601

Sort: Relevancy | Date

News Daily News

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

L.A. McKeown

June 30, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News EAS 2017

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

Yael L. Maxwell

April 27, 2017

News Daily News

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

Caitlin E. Cox

April 25, 2017

News Daily News

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

Michael O'Riordan

April 24, 2017

News Daily News

If You Don’t Take Your Stroke Meds, This App Will Tell on You

Todd Neale

April 18, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Shelley Wood

February 28, 2017

Ticagrelor May Be Useful for Secondary Prevention After Stroke, TIA If Initial Event Is Related to Atherosclerosis

News Conference News ISC 2017

Ticagrelor May Be Useful After Stroke, TIA if Event Related to Atherosclerosis

Todd Neale

February 28, 2017

Advertisement

Poor Prescription Adherence After Acute MI Continues to Vex Researchers

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

If You Don’t Take Your Stroke Meds, This App Will Tell on You

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Herbals and the Heart: New Review Seeks to Sum Up Dearth of Data on Effects and Hazards

Ticagrelor May Be Useful After Stroke, TIA if Event Related to Atherosclerosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content